DASHENLIN PHARMACEUTICAL GROUP CO., LTD.

News DaShenLin Pharmaceutical Group Co., Ltd.

Stocks

603233

CNE100002RG2

Drug Retailers

End-of-day quote Shanghai S.E. 2026-09-04			5-day change	1st Jan Change
18.79 ^CNY	+1.51%		+3.53%	+6.64%

09-02	Jefferies Adjusts DaShenLin Pharmaceutical Group's Price Target to 15 Yuan From 12 Yuan, Keeps at Underperform	MT
08-24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

All News

Mentions Relevance

09-02	Jefferies Adjusts DaShenLin Pharmaceutical Group's Price Target to 15 Yuan From 12 Yuan, Keeps at Underperform	MT
08-24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-24	Dashenlin Pharma's Q1 Profit Rises 11%	MT
04-24	Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4%	MT
04-23	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Dashenlin pharmaceutical 2025 net profit up 35.0% y/y	RE
04-22	Sipai Health to Sell Stake in Pharmacy Operator to Dashenlin Pharmaceutical For RMB 51.7 Million	MT
04-22	DaShenLin Pharmaceutical Group Co., Ltd. signed a equity transfer agreement to acquire Sipai Zhihe Technology Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.	CI
25-10-29	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-08-28	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-15	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
24-09-19	Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.	CI
24-09-17	DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million.	CI
24-08-30	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-02	Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.	CI
24-05-06	DaShenLin Pharmaceutical Group Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on April 1, 2024.	CI
24-04-28	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-27	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-03-04	Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares	MT
24-01-22	DaShenLin Pharmaceutical Group Co., Ltd. cancelled the transaction announced on January 19, 2023	CI
23-11-27	Dashenlin Pharmaceutical to Boost Stake in Local Pharmacy Chain to 66% For 30 Million Yuan	MT
23-11-24	DaShenLin Pharmaceutical Group Co., Ltd. agreed to acquire 15% stake in Chongqing Wanjiayan Pharmacy Chain Co., Ltd from Chongqing Wanjiayan Health Industry Group Co., Ltd. and Bai Run for CNY 30 million.	CI
23-10-29	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI